JPRN-UMIN000007714已完成未知
The effects of the combination therapy of DPP-4 inhibitor alogliptin and alfa-glucosidase inhibitor on markers of inflammation and oxidative stress - comparison between Acarbose and Voglibose - Combination therapy of DPP-4 inhibitor and alfa-glucosidase inhibitor
Department of Internal Medicine, School of Medicine, Keio University0 个研究点目标入组 40 人开始时间: 2012年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. type 1 diabetes mellitus 2. diabetes ketoacidosis, coma, or pre-coma 3. patients with severe infection, severe trauma, or in perioperative period 4. patients who have allergy to the medicine used in this trial 5.(possible) pregnant women
研究者
相似试验
已完成
不适用
Effect of combination therapy with DPP-4 inhibitor and omega 3-fatty acid on glycemic control in type2 diabetes with dyslipidemiaType 2 diabetes mellitusJPRN-UMIN000010397Yokohama City University Medical Center150
已完成
不适用
Effects of concomitant administration of DPP-4 and SGLT2 inhibitors in Japanese patients with type 2 diabetesType 2 diabetesJPRN-UMIN000026442agoya University220
已完成
不适用
Efficacy of combination therapy of DPP-4 inhibitor and alpha glucosidase inhibitor in insurin treaaed type 2 diabetes.Type 2 diabetesJPRN-UMIN000011815ational Center for Global Health and Medicine5
已完成
不适用
Efficacy of conbination therapy of DPP4-inhibitor and alpha-GI for type-2 diabetes patient.type-2 diabetes mellitusJPRN-UMIN000008051Third Department of Internal Medicine, Tokyo Medical University5
进行中（未招募）
不适用
valuation of the effect of a new drug for diabetes on atherosclerosis in patients with primary failure metformiType 2 diabetesMedDRA version: 14.1Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000152-34-ITAZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA64